These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E. Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160 [Abstract] [Full Text] [Related]
4. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. Steen Carlsson K, Astermark J, Donfield S, Berntorp E. Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509 [Abstract] [Full Text] [Related]
5. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Valentino LA. Haemophilia; 2009 May; 15(3):733-42. PubMed ID: 19298380 [Abstract] [Full Text] [Related]
6. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G, NovoSeven trial (F7HAEM-1510) investigators. Thromb Haemost; 2006 Apr; 95(4):600-5. PubMed ID: 16601828 [Abstract] [Full Text] [Related]
8. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain. Jimenez-Yuste V, Núñez R, Romero JA, Montoro B, Espinós B. Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100 [Abstract] [Full Text] [Related]
16. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Joshi AV, Stephens JM, Munro V, Mathew P, Botteman MF. Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427 [Abstract] [Full Text] [Related]
18. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain. Villarrubia R, Oyagüez I, Álvarez-Román MT, Mingot-Castellano ME, Parra R, Casado MA. Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214 [Abstract] [Full Text] [Related]
19. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Parameswaran R, Shapiro AD, Gill JC, Kessler CM, HTRS Registry Investigators. Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910 [Abstract] [Full Text] [Related]
20. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors. Hay JW, Zhou ZY. Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802 [Abstract] [Full Text] [Related] Page: [Next] [New Search]